Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3

Abstract Background Midostaurin combined with chemotherapy is currently used to treat newly diagnosed acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 (FLT3)-mutations. However, midostaurin acts as an antagonist to some chemotherapeutic agents in leukemia cell lines without FLT3...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Hao Lu, Xiang-qin Weng, Yan Sheng, Jing Wu, Hui-min Xi, Xun Cai
Format:	Article
Language:	English
Published:	BMC 2022-07-01
Subjects:	Acute myeloid leukemia All-trans retinoic acid Apoptosis Differentiation Midostaurin
Online Access:	https://doi.org/10.1186/s12885-022-09828-2